Plourde_BreastCancerSymposium_prev

by | Jan 3, 2020 | 0 comments

An Open-label, Randomized, Multi-center Phase 2 Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation

Submit a Comment

Your email address will not be published. Required fields are marked *